Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report

Salvage Therapy With Selpercatinib for RET-Rearranged NSCLC With Pralsetinib-Related Pneumonitis and Leptomeningeal Disease: A Case Report

Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced RET-rearranged NSCLC. We present a case of pralsetinib-related pneumonitis and leptomeningeal and brain metastases progression during treatment suspension for pneumonitis. During recovery, selpercatinib administra...

Full description

Bibliographic Details
Main Authors: Paolo D. d'Arienzo, MD, MRCP, Niamh Cunningham, MBBS, BSc, MRCP, Hazel O’Sullivan, MBBchBAO, MRCPI, Charlotte Grieco, MBBS, MRCP, Virjen Patel, MbChB, BSc, FRCR, Sanjay Popat, PhD, FRCP
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:JTO Clinical and Research Reports
Subjects:
Selpercatinib
Pralsetinib
RET fusion
Leptomeningeal disease
NSCLC
Case Report
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364323001248
Description
Summary:Selpercatinib and pralsetinib are RET inhibitors with substantial activity in advanced RET-rearranged NSCLC. We present a case of pralsetinib-related pneumonitis and leptomeningeal and brain metastases progression during treatment suspension for pneumonitis. During recovery, selpercatinib administration led to rapid neurologic response and complete intracranial response and allowed pneumonitis resolution. This case supports the safety of selpercatinib in patients with pneumonitis on pralsetinib and highlights its marked efficacy in leptomeningeal disease.
ISSN:2666-3643

Similar Items